New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareFollistatin 344 vs MK-677 (Ibutamoren)

Follistatin 344 vs MK-677 (Ibutamoren)

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
Follistatin 344
Growth Hormone Peptides
MK-677 (Ibutamoren)
Summary
Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
Half-Life
~24–36 hours
24 hours
Admin Route
SubQ, IM
Oral
Research
Typical Dose
100 mcg
10–25 mg
Frequency
Once daily
Once daily
Key Benefits
  • Inhibits myostatin — removes muscle growth ceiling
  • Significant increases in muscle mass and strength
  • Reduces fat mass
  • Promotes bone density
  • May stimulate hair follicle cycling
  • Anti-fibrotic effects in muscle tissue
  • Synergistic with IGF-1 and other anabolic peptides
  • Increases lean muscle mass
  • Enhances bone density
  • Improves sleep quality and REM sleep
  • Accelerates recovery from training
  • Increases appetite
  • May improve skin elasticity and appearance
  • Supports fat loss while maintaining muscle
  • Oral administration — no injections required
  • 24-hour half-life allows once-daily dosing
Side Effects
  • Muscle soreness (from rapid hypertrophy)
  • Potential reproductive effects (activin inhibition)
  • Unknown long-term safety profile
  • Possible esophageal effects at high doses (animal data)
  • Increased appetite (significant in some users)
  • Water retention and puffiness
  • Elevated blood glucose / insulin resistance (monitor in diabetics)
  • Lethargy initially
  • +2 more
Stacks With